Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News argenx SE ARGX

argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland.


Recent & Breaking News (NDAQ:ARGX)

argenx Announces European Commission Approval of VYVGART(TM) (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis

GlobeNewswire 11 hours ago

argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022

GlobeNewswire July 28, 2022

argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update

GlobeNewswire July 28, 2022

argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022

GlobeNewswire July 21, 2022

argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe

GlobeNewswire June 24, 2022

argenx to Present at Upcoming Investor Conferences

GlobeNewswire June 1, 2022

argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis

GlobeNewswire May 31, 2022

argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases

GlobeNewswire May 19, 2022

argenx announces results of Annual General Meeting of Shareholders

GlobeNewswire May 10, 2022

argenx Reports First Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire May 5, 2022

argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

GlobeNewswire May 5, 2022

argenx to Present at BofA Securities 2022 Healthcare Conference

GlobeNewswire May 4, 2022

argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022

GlobeNewswire April 28, 2022

argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting

GlobeNewswire April 5, 2022

argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting

Business Wire April 1, 2022

argenx announces full exercise of underwriters' option to purchase additional ADSs

GlobeNewswire March 29, 2022

argenx announces Annual General Meeting of Shareholders on May 10, 2022

GlobeNewswire March 29, 2022

argenx announces closing of global offering

GlobeNewswire March 28, 2022

argenx raises $700 million in gross proceeds in a global offering

GlobeNewswire March 23, 2022

argenx announces launch of proposed global offering

GlobeNewswire March 22, 2022